ArticleLife science alliance2021
Engineered RNA biosensors enable ultrasensitive SARS-CoV-2 detection in a simple color and luminescence assay.
Article in Life science alliance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Trends of nucleic acid - based point-of-care diagnostics for infectious diseases.Journal of biological engineering · 2026Review
- Genomic diversity analysis enables development of pan-Dengue Toehold RNA sensors.PLoS neglected tropical diseases · 2026Article
- Toehold-VISTA: a machine learning approach to decipher programmable RNA sensor-target interactions.Nucleic acids research · 2026Article
- Synthetic toehold biosensors for detectingFrontiers in microbiology · 2026Article
- Current biosensing strategies based on in vitro T7 RNA polymerase reaction.Biotechnology notes (Amsterdam, Netherlands) · 2025Review
- Nucleic Acid Based Testing (NABing): A Game Changer Technology for Public Health.Molecular biotechnology · 2024Review
- Rapid assays of SARS-CoV-2 virus and noble biosensors by nanomaterials.Nano convergence · 2024Review
- BRET-based biosensors for SARS-CoV-2 oligonucleotide detection.Frontiers in bioengineering and biotechnology · 2024Article
- Toehold switch plus signal amplification enables rapid detection.Biotechnology journal · 2023Article
- Evaluation of real-time NASBA assay for the detection of SARS-CoV-2 compared with real-time PCR.Irish journal of medical science · 2023Article
- Designing and fabrication of electrochemical nano-biosensor for the fast detection of SARS-CoV-2-RNA.Scientific reports · 2023Article
- Engineering Toehold-Mediated Switches for Native RNA Detection and Regulation in Bacteria.Journal of molecular biology · 2022Review
- Progress and Challenges of Point-of-Need Photonic Biosensors for the Diagnosis of COVID-19 Infections and Immunity.Biosensors · 2022Review
- Isothermal amplification-assisted diagnostics for COVID-19.Biosensors & bioelectronics · 2022Review
- Diagnostic assay and technology advancement for detecting SARS-CoV-2 infections causing the COVID-19 pandemic.Analytical and bioanalytical chemistry · 2022Review
- Update on the Development of Toehold Switch-Based Approach for Molecular Diagnostic Tests of COVID-19.Journal of nucleic acids · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
The continued resurgence of the COVID-19 pandemic with multiple variants underlines the need for diagnostics that are adaptable to the virus. We have developed toehold RNA-based sensors across the SARS-CoV-2 genome for direct and ultrasensitive detection of the virus and its prominent variants. Here, isothermal amplification of a fragment of SARS-CoV-2 RNA coupled with activation of our biosensors leads to a conformational switch in the sensor. This leads to translation of a reporter protein, for example, LacZ or nano-lantern that is easily detected using color/luminescence. By optimizing RNA amplification and biosensor design, we have generated a highly sensitive diagnostic assay that is capable of detecting as low as 100 copies of viral RNA with development of bright color. This is easily visualized by the human eye and quantifiable using spectrophotometry. Finally, this PHAsed NASBA-Translation Optical Method (PHANTOM) using our engineered RNA biosensors efficiently detects viral RNA in patient samples. This work presents a powerful and universally accessible strategy for detecting COVID-19 and variants. This strategy is adaptable to further viral evolution and brings RNA bioengineering center-stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.